Parallel Advisors LLC Sells 171 Shares of Agilent Technologies, Inc. (NYSE:A)

Parallel Advisors LLC decreased its position in Agilent Technologies, Inc. (NYSE:A) by 3.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,463 shares of the medical research company’s stock after selling 171 shares during the period. Parallel Advisors LLC’s holdings in Agilent Technologies were worth $734,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. CKW Financial Group lifted its stake in Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after acquiring an additional 100 shares during the period. Global X Japan Co. Ltd. lifted its stake in Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after acquiring an additional 116 shares during the period. RPg Family Wealth Advisory LLC purchased a new stake in Agilent Technologies in the third quarter worth $38,000. Hanson & Doremus Investment Management lifted its stake in Agilent Technologies by 66.5% in the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock worth $35,000 after acquiring an additional 105 shares during the period. Finally, OFI Invest Asset Management purchased a new stake in Agilent Technologies in the fourth quarter worth $37,000. Institutional investors own 87.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A has been the subject of a number of research analyst reports. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Wells Fargo & Company lowered their price objective on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research report on Monday, December 9th. Barclays raised Agilent Technologies from an “underweight” rating to an “equal weight” rating and raised their price objective for the company from $135.00 to $145.00 in a research report on Monday, February 10th. Sanford C. Bernstein lowered their price objective on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. lowered their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $146.15.

Insider Buying and Selling

In other Agilent Technologies news, VP Rodney Gonsalves sold 1,908 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the sale, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. The trade was a 8.05 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.26% of the stock is owned by corporate insiders.

Agilent Technologies Price Performance

A opened at $120.23 on Friday. Agilent Technologies, Inc. has a 1 year low of $117.17 and a 1 year high of $155.35. The stock has a 50-day moving average price of $137.07 and a 200-day moving average price of $137.45. The firm has a market cap of $34.28 billion, a PE ratio of 27.64, a P/E/G ratio of 3.45 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The company had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Sell-side analysts predict that Agilent Technologies, Inc. will post 5.57 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be issued a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.83%. Agilent Technologies’s payout ratio is 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.